Article
Calciphylaxis as a Rare Complication Associated with Pemigatinib Treatment—A Case Report
2026-03-19
Abstract excerpt
Fibroblast growth factor receptor 2 (FGFR2) inhibitors such as pemigatinib are targeted therapies for cholangiocarcinoma with FGFR2 alterations. While generally well tolerated, they are associated with unique adverse events. Calciphylaxis, a potentially fatal vascular calcification disorder, is a rare complication. We present a 43-year-old woman with metastatic intrahepatic cholangiocarcinoma harboring an FGFR2 fu...
Topics
Open a Topic to create a Post that cites this publication.
Identifiers and source
- Literature Corpus work
- 549e023d-e256-565f-af8e-eee99cd9f414
- DOI
- 10.20944/preprints202603.1562.v1
